S-H.I. Ou

873 total citations
34 papers, 642 citations indexed

About

S-H.I. Ou is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, S-H.I. Ou has authored 34 papers receiving a total of 642 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pulmonary and Respiratory Medicine, 28 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in S-H.I. Ou's work include Lung Cancer Treatments and Mutations (29 papers), Colorectal Cancer Treatments and Studies (14 papers) and Lung Cancer Research Studies (10 papers). S-H.I. Ou is often cited by papers focused on Lung Cancer Treatments and Mutations (29 papers), Colorectal Cancer Treatments and Studies (14 papers) and Lung Cancer Research Studies (10 papers). S-H.I. Ou collaborates with scholars based in United States, France and Spain. S-H.I. Ou's co-authors include Jason A. Zell, Hoda Anton‐Culver, Dan J. Raz, David M. Jablons, David R. Gandara, Alice T. Shaw, Benjamin Solomon, D. Ross Camidge, J. W. Clark and A. John Iafrate and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and CHEST Journal.

In The Last Decade

S-H.I. Ou

32 papers receiving 624 citations

Peers

Countries citing papers authored by S-H.I. Ou

Since Specialization

Citations

This map shows the geographic impact of S-H.I. Ou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S-H.I. Ou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S-H.I. Ou more than expected).

Fields of papers citing papers by S-H.I. Ou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S-H.I. Ou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S-H.I. Ou. The network helps show where S-H.I. Ou may publish in the future.

Co-authorship network of co-authors of S-H.I. Ou

This figure shows the co-authorship network connecting the top 25 collaborators of S-H.I. Ou. A scholar is included among the top collaborators of S-H.I. Ou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S-H.I. Ou. S-H.I. Ou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC) 2025 ·Journal of Thoracic Oncology ·Salman R. Punekar, (unknown), Jia Luo, S-H.I. Ou, (unknown), (unknown), Ignacio Garrido‐Laguna, (unknown), (unknown), Andreas Saltos, Priyam Mitra, Aparna Hegde, (unknown), Minoti Hiremath, Kathryn C. Arbour	1
2	549O Adagrasib with or without cetuximab in patients with KRASG12C-mutated colorectal cancer (CRC): Analysis of tumor biomarkers and genomic alterations 2023 ·Annals of Oncology ·(unknown), (unknown), (unknown), S-H.I. Ou, Alexander I. Spira, Pasi A. Jänne, Nataliya V. Uboha, Yousuf Gaffar, (unknown), Cloud P. Paweletz, (unknown), (unknown), Thian Kheoh, Kenna Anderes, (unknown), (unknown), (unknown)	5
3	14MO Updated efficacy and safety of taletrectinib in patients (pts) with ROS1+ non-small cell lung cancer (NSCLC) 2023 ·Journal of Thoracic Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), S-H.I. Ou, (unknown)	7
4	81TiP NVL-655, a selective anaplastic lymphoma kinase (ALK) inhibitor, in patients with advanced ALK-positive solid tumors: The phase I/II ALKOVE-1 study 2023 ·Journal of Thoracic Oncology ·(unknown), S-H.I. Ou, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	5
5	78TiP Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study 2022 ·Annals of Oncology ·Benjamin Besse, Melissa L. Johnson, S-H.I. Ou, Shirish M. Gadgeel, (unknown), Jung‐Yaw Lin, (unknown), Anthonie J. van der Wekken, Antonio Calles, (unknown), D. Ross Camidge, Yasir Y. Elamin, (unknown), Stephen V. Liu, Jessica R. Bauman, Daniel Haggstrom, (unknown), Henry E. Pelish, Viola W. Zhu, A. Drilon	1
6	LBA24 KRYSTAL-1: Updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation 2022 ·Annals of Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), S-H.I. Ou, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	20
7	1224P Systematic review and meta-analysis of immunotherapy effectiveness for pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertions 2021 ·Annals of Oncology ·Petros Christopoulos, S-H.I. Ou, Jianchang Lin, (unknown), (unknown), Yu Yin, Veronica Bunn, Hui‐Ming Lin, Minal Mehta, Michael Thomas	2
8	LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation 2021 ·Annals of Oncology ·(unknown), Rona Yaeger, Melissa L. Johnson, Alexander I. Spira, Samuel J. Klempner, Minal Barve, James G. Christensen, Andrew Chi, Hirak Der‐Torossian, Karen Velastegui, Thian Kheoh, S-H.I. Ou	52
9	1211P Indirect comparison of mobocertinib and standard of care in platinum-pretreated patients with NSCLC with EGFR exon 20 insertion 2021 ·Annals of Oncology ·S-H.I. Ou, Huamao Mark Lin, (unknown), Yuping Yin, Shuai Jin, Jianwen Lin, Minal Mehta, Danny Nguyen, Joel W. Neal	2
10	539P Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study 2020 ·Annals of Oncology ·Anthony P. Conley, George D. Demetri, Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares, Philippe A. Cassier, Salvatore Siena, M-J. Ahn, Gary L. Buchschacher, Takashi Seto, Cheng Ean Chee, Maciej Krzakowski, S-H.I. Ou, Christian Grohé, Vittorina Zagonel, Alexander I. Spira, (unknown), (unknown), Elisabeth Piault, Christian Rolfo	2
11	1362P Clinical and real-world outcomes in patients with epidermal growth factor receptor (EGFR) exon 20 insertions in non-small cell lung cancer (NSCLC): A meta-analysis 2020 ·Annals of Oncology ·(unknown), (unknown), Anna Forsythe, (unknown), S-H.I. Ou	6
12	P1.01-86 Occurrence of de Novo Dual HER2/HER3 or HER2/EGFR TMD Mutations: Extending the Spectrum of Targetable Mono-HER2 TMD in NSCLC? 2019 ·Journal of Thoracic Oncology ·S-H.I. Ou, Alexa B. Schrock, Eduard V. Bocharov, (unknown), Russell W. Madison, (unknown), Virginia L. Miller, Barbara D. Alexander, Hatim Husain, Jonathan W. Riess, Simak Ali, Vamsidhar Velcheti	1
13	P2.13-46 Comprehensive Investigation of ERBB2 Transmembrane Domain Mutations (V659/G660) in 12,833 Chinese Lung Cancer Patients 2018 ·Journal of Thoracic Oncology ·Ruoxi Yu, (unknown), Hua Bao, S-H.I. Ou, Xifeng Wu	0
14	158P Afatinib in patients with EGFR mutation-positive (EGFRm+) NSCLC harbouring uncommon mutations: Overview of clinical data 2018 ·Journal of Thoracic Oncology ·Angela Märten, Nobuyuki Yamamoto, Chong‐Jen Yu, S-H.I. Ou, (unknown), Yi‐Long Wu	1
15	OA02.03 Clinical Activity of Lorlatinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer: Phase 2 Study Cohort EXP-6 2018 ·Journal of Thoracic Oncology ·S-H.I. Ou, Alice T. Shaw, G. Riely, Rita Chiari, Jessica R. Bauman, Jill S. Clancy, (unknown), Gerson Peltz, Antonello Abbattista, Benjamin Solomon	16
16	Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study 2017 ·Annals of Oncology ·Tony Mok, Solange Peters, D. Ross Camidge, S-H.I. Ou, Jin Seok Ahn, E.H. Tan, (unknown), Jin Sun Lee, Byoung Chul Cho, Sarayut Lucien Geater, Virote Sriuranpong, Jcm Ho, (unknown), Ali Zeaiter, Bogdan Balas, (unknown), Emmanuel Mitry, Peter N. Morcos, Dongwook Kim	8
17	Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study 2017 ·Annals of Oncology ·Shirish M. Gadgeel, Solange Peters, Tony Mok, Alice T. Shaw, Dongwook Kim, S-H.I. Ou, M. Pérol, Rafał Dziadziuszko, Jin Seok Ahn, Rafael Rosell, Ali Zeaiter, Emmanuel Mitry, (unknown), Bogdan Balas, D. Ross Camidge	13
18	A Large Retrospective Analysis of Pemetrexed (PEM) Activity in Patients (PTS) with Alk-Positive (Alk+) Non-Small Cell Lung Cancer (NSCLC) Prior to Crizotinib (CRIZ) Treatment 2012 ·Annals of Oncology ·Giorgio V. Scagliotti, (unknown), Alice T. Shaw, S-H.I. Ou, Gregory J. Riely, Scott Gettinger, Benjamin Besse, Keith D. Wilner, Yiyun Tang, Cynthia Huang Bartlett	1
19	Natural History of Stage I Non-Small Cell Lung Cancer 2007 ·CHEST Journal ·Dan J. Raz, Jason A. Zell, S-H.I. Ou, David R. Gandara, Hoda Anton‐Culver, David M. Jablons	230
20	Efficacy and Safety of Single-Agent Axitinib (AG-013736; AG) in Patients with Advanced Non–Small-Cell Lung Cancer (NSCLC): A Phase II Trial 2007 ·Clinical Lung Cancer ·Joan H. Schiller, Joachim von Pawel, Timothy Larson, S-H.I. Ou, Steven Limentani, Alan B. Sandler, Everett E. Vokes, (unknown), Katherine Liau, Paul Bycott	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact